Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX) is pleased to announce financial results for the March 2023 Quarter. Highlights…
Highlights AROA has been awarded a group purchasing agreement for its Myriad™ and Symphony™ products, with Premier, Inc. – a…
Read MoreFirst of its kind study shows promising results for combined use of negative pressure wound therapy and AROA’s EndoformTM High…
Read MoreAroa Biosurgery Limited (ASX: ARX, ‘AROA’ or the ‘Company’) is pleased to provide an update on its activities for the…
Read MoreToday Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23. With fewer COVID-19 related disruptions,…
Read MoreAroa Biosurgery, (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor, Dr. Catherine Mohr as a…
Read MoreSoft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘AROA’ or the ‘Company’)advises that following recent incidences of COVID-19 amongst staff…
Read MoreToday Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23. With fewer COVID-19 related disruptions,…
Read MoreHighlights A retrospective analysis of real-world data published in the ‘International Wound Journal’ compared the wound closure times for diabetic…
Read MoreHighlights• AROA’s Myriad Matrix™ is further validated in a clinical study and peer-reviewed publication in Journal of Wound Care.• Study…
Read More